Your browser doesn't support javascript.
loading
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women.
Marker, Katie M; Zavala, Valentina A; Vidaurre, Tatiana; Lott, Paul C; Vásquez, Jeannie Navarro; Casavilca-Zambrano, Sandro; Calderón, Mónica; Abugattas, Julio E; Gómez, Henry L; Fuentes, Hugo A; Picoaga, Ruddy Liendo; Cotrina, Jose M; Neciosup, Silvia P; Castañeda, Carlos A; Morante, Zaida; Valencia, Fernando; Torres, Javier; Echeverry, Magdalena; Bohórquez, Mabel E; Polanco-Echeverry, Guadalupe; Estrada-Florez, Ana P; Serrano-Gómez, Silvia J; Carmona-Valencia, Jenny A; Alvarado-Cabrero, Isabel; Sanabria-Salas, María Carolina; Velez, Alejandro; Donado, Jorge; Song, Sikai; Cherry, Daniel; Tamayo, Lizeth I; Huntsman, Scott; Hu, Donglei; Ruiz-Cordero, Roberto; Balassanian, Ronald; Ziv, Elad; Zabaleta, Jovanny; Carvajal-Carmona, Luis; Fejerman, Laura.
Afiliação
  • Marker KM; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California.
  • Zavala VA; Division of Epidemiology, School of Public Health, University of California Berkeley, Berkeley, California.
  • Vidaurre T; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California.
  • Lott PC; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Vásquez JN; UC Davis Genome Center, University of California, Davis, Davis, California.
  • Casavilca-Zambrano S; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Calderón M; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Abugattas JE; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Gómez HL; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Fuentes HA; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Picoaga RL; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Cotrina JM; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Neciosup SP; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Castañeda CA; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Morante Z; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Valencia F; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Torres J; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Echeverry M; Unidad de Investigación en Enfermedades Infecciosas, Instituto Mexicano del Seguro Social; México City, México.
  • Bohórquez ME; Grupo de Citogenética, Filogenia y Evolución de Poblaciones, Facultades de Ciencias y Facultad de Ciencias de la Salud, Universidad del Tolima, Ibagué, Colombia.
  • Polanco-Echeverry G; Grupo de Citogenética, Filogenia y Evolución de Poblaciones, Facultades de Ciencias y Facultad de Ciencias de la Salud, Universidad del Tolima, Ibagué, Colombia.
  • Estrada-Florez AP; UC Davis Genome Center, University of California, Davis, Davis, California.
  • Serrano-Gómez SJ; UC Davis Genome Center, University of California, Davis, Davis, California.
  • Carmona-Valencia JA; Grupo de Citogenética, Filogenia y Evolución de Poblaciones, Facultades de Ciencias y Facultad de Ciencias de la Salud, Universidad del Tolima, Ibagué, Colombia.
  • Alvarado-Cabrero I; Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá, Colombia.
  • Sanabria-Salas MC; Dinamica IPS, Medellín, Colombia.
  • Velez A; Hospital de Oncología de Centro Médico Nacional Siglo XXI, México City, México.
  • Donado J; Subdirección de Investigaciones - Instituto Nacional de Cancerología, Bogotá, Colombia.
  • Song S; Dinamica IPS, Medellín, Colombia.
  • Cherry D; Hospital Pablo Tobon Uribe, Medellín, Colombia.
  • Tamayo LI; Hospital Pablo Tobon Uribe, Medellín, Colombia.
  • Huntsman S; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California.
  • Hu D; Department of Medicine, University of California San Diego, San Diego, California.
  • Ruiz-Cordero R; Department of Public Health Sciences, University of Chicago, Chicago, Illinois.
  • Balassanian R; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California.
  • Ziv E; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California.
  • Zabaleta J; Department of Pathology, University of California, San Francisco, California.
  • Carvajal-Carmona L; Department of Pathology, University of California, San Francisco, California.
  • Fejerman L; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California.
Cancer Res ; 80(9): 1893-1901, 2020 05 01.
Article em En | MEDLINE | ID: mdl-32245796
ABSTRACT
Women of Latin American origin in the United States are more likely to be diagnosed with advanced breast cancer and have a higher risk of mortality than non-Hispanic White women. Studies in U.S. Latinas and Latin American women have reported a high incidence of HER2 positive (+) tumors; however, the factors contributing to this observation are unknown. Genome-wide genotype data for 1,312 patients from the Peruvian Genetics and Genomics of Breast Cancer Study (PEGEN-BC) were used to estimate genetic ancestry. We tested the association between HER2 status and genetic ancestry using logistic and multinomial logistic regression models. Findings were replicated in 616 samples from Mexico and Colombia. Average Indigenous American (IA) ancestry differed by subtype. In multivariate models, the odds of having an HER2+ tumor increased by a factor of 1.20 with every 10% increase in IA ancestry proportion (95% CI, 1.07-1.35; P = 0.001). The association between HER2 status and IA ancestry was independently replicated in samples from Mexico and Colombia. Results suggest that the high prevalence of HER2+ tumors in Latinas could be due in part to the presence of population-specific genetic variant(s) affecting HER2 expression in breast cancer.

SIGNIFICANCE:

The positive association between Indigenous American genetic ancestry and HER2+ breast cancer suggests that the high incidence of HER2+ subtypes in Latinas might be due to population and subtype-specific genetic risk variants.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Hispânico ou Latino / Receptor ErbB-2 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: America do sul / Colombia / Mexico / Peru Idioma: En Revista: Cancer Res Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Hispânico ou Latino / Receptor ErbB-2 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: America do sul / Colombia / Mexico / Peru Idioma: En Revista: Cancer Res Ano de publicação: 2020 Tipo de documento: Article